Kavita Khanijow, MD
Urogynecology and Reconstructive Pelvic Surgery · New Port Richey, FLNPI 1346534948
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,805 of the $7,904 with a category attached, or 73.4%. 28 manufacturers reported payments, led by Axonics, Inc. at 55.0% of the total. Reporting peaked in 2022 at $3,787 and has fallen 84.9% since, to $571 in 2025.
Across 258 payments — averaging $30.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$4K
- Astellas Pharma US Inc$750
- AbbVie$416
- Boston Scientific$413
- Medtronic$385
- Caldera Medical, Inc$277
- plus $1K from 22 others
What the payments were for
- Speaking & faculty fees$2733%
- Travel & lodging$1,48719%
- Food & beverage$5,80573%
- Education$3134%
- Gifts$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 114 | $4,345 |
| Astellas Pharma US Inc | 25 | $750 |
| AbbVie(2 entities) | 23 | $416 |
| Boston Scientific | 10 | $413 |
| Medtronic(2 entities) | 13 | $385 |
| Caldera Medical, Inc | 4 | $277 |
| Coloplast | 12 | $228 |
| Sumitomo Pharma America, Inc. | 8 | $187 |
| Myovant Sciences Inc. | 8 | $148 |
| Hologic Sales And Service, LLC | 6 | $142 |
| Pfizer | 4 | $86 |
| Exeltis, USA Inc. | 4 | $81 |
| Coopersurgical, Inc. | 4 | $72 |
| Therapeuticsmd, Inc. | 4 | $57 |
| Evofem Biosciences, Inc. | 3 | $53 |
| Merck | 2 | $37 |
| Millicent US Inc | 2 | $37 |
| Meditrina | 2 | $28 |
| Palette Life Sciences, Inc. | 1 | $23 |
| ABC Home Medical Supply, Inc. | 1 | $20 |
| Urovant Sciences Inc | 1 | $18 |
| Ascend Therapeutics US, LLC | 1 | $17 |
| Valencia Technologies Corporation | 1 | $15 |
| Dentsply IH AB | 1 | $15 |
| Laborie Medical Technologies Corp. | 1 | $14 |
| Roche Diagnostics Corporation | 1 | $14 |
| AMAG Pharmaceuticals, Inc. | 1 | $13 |
| Mayne Pharma Commercial LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,904 in reported general payments places this provider in the 65th percentile of 81 urogynecology and reconstructive pelvic surgery providers in Florida.
See all urogynecology and reconstructive pelvic surgery providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 158 | $135,285 |
| GemtesaVibegron | 79 | $68,025 |
| Methenamine Hippurate | 181 | $19,655 |
| Estradiol | 270 | $15,511 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 209 | $3,353 |
| Oxybutynin Chloride ErOxybutynin Chloride | 48 | $2,487 |
| Estradiol (Twice Weekly)Estradiol | 13 | $1,745 |
| Clobetasol Propionate | 62 | $1,702 |
| Fosfomycin Tromethamine | 11 | $1,365 |
| Metronidazole | 98 | $861 |
| Amitriptyline Hcl | 112 | $812 |
| Fluconazole | 70 | $476 |
| ProgesteroneProgesterone, Micronized | 18 | $405 |
| Tamsulosin Hcl | 23 | $220 |
| Ciprofloxacin Hcl | 60 | $215 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $750 | $135,285158 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $187 | $68,02579 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 81 urogynecology and reconstructive pelvic surgery providers in Florida.
Other urogynecology and reconstructive pelvic surgery in New Port Richey
- Nathan KowOrlando$116K
- Amir ShariatiCoconut Creek$106K
- Charbel SalamonOrlando$100K
- Allison WymanTampa$69K
- Nicole SzellLargo$54K
- Jose Lazaro WeissOviedo$28K
- Paul PettitJacksonville$27K
- Arash RahiCoconut Creek$23K
- Moises VirellesWellington$21K
- Marja SprockRockledge$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.